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Although the use of bioresorbable materials in stent production is thought to
improve long-term safety compared to their durable counterparts, a recent FDA
report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent
showed an increased occurrence of major adverse cardiac events and thrombosis
in comparison to the metallic control. In order to overcome the issues of first
generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-
L-lactide-co-ε-caprolactone copolymers with varying lactide-to-caprolactone content is
developed using a novel one-step PEG-functionalization and copolymerization strategy.
This approach represents a new facile way toward surface enhancement for cellular
interaction, which is shown by screening these materials regarding their cyto- and
hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte
activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer
composition, it is possible to gradually affect endothelial and platelet adhesion
which allows fine-tuning of the biological response based on polymer chemistry. All
polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and
presented non-hemolytic (<2% hemolysis rate) behavior except for PLCL-PEG 55:45
which presented hemolysis rate of 2.5% ± 0.5. Water contact angles were reduced
in the polymers containing PEG functionalization (PLLA-PEG: 69.8◦ ± 2.3, PCL-PEG:
61.2◦ ± 7.5) versus those without (PLLA: 79.5◦ ± 3.2, PCL: 76.4◦ ± 10.2) while the
materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated
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best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as
best candidates for cardiovascular implant use from a cytocompatibility perspective
across the spectrum of testing completed. Altogether, these polymers are excellent
innovative materials suited for an application in stent manufacture due to the ease in
translation of this one-step synthesis strategy to device production and their excellent
in vitro cyto- and hemocompatibility.
Keywords: poly-L-lactide, poly-ε-caprolactone, polyethylene glycol, bioresorbable, cytocompatibility
INTRODUCTION
Stents are used in percutaneous coronary intervention to restore
blood flow in patients with coronary artery disease (CAD)
which is characterized by the occlusion of a coronary artery
due to plaque formation (Garg and Serruys, 2010; Li et al.,
2010). Researchers are dedicated to the development of new
biocompatible materials for use in stent devices, that on the
one hand provide enough strength for vessel support during
constrictive re-modeling while also allowing for good cyto-
and hemocompatibility (Van Oeveren et al., 1999; Williams,
2008; Huang et al., 2014; Zhang et al., 2014; Blok et al.,
2016). Complications still arise from stent placement, the main
issues being in-stent restenosis and stent thrombosis resulting
from inadequate mechanical properties or poor biocompatibility
(Zhang et al., 2014). Drug Eluting Stents (DES) were successful
in reducing the rate of in-stent restenosis (Khan et al., 2012),
however, the requirement of longer dual antiplatelet therapy
(DAPT) to prevent stent thrombosis means that they are
not suitable for all patients. In addition, complications have
arisen relating to DES with reported cases of late thrombosis,
hypersensitivity and delayed healing (Al-Dehneh et al., 2010).
A major disadvantage of BMS and DES stent devices is the
permanence of the scaffold associated with adverse events
including stent jailing, side vessel obstruction, impairment of
vessel geometries and the need for long term anti-coagulant
therapy (Waksman, 2006; Meraj et al., 2015).
Fully absorbable stent technologies are the freshest
development in this sector and introduce a new paradigm
in CAD treatment (Tenekecioglu et al., 2016). Scaffold resorption
after vessel repair is thought to offer several advantages including
a reduced risk of late stent thrombosis, facilitation of repeat
treatments, restoration of vasomotion and freedom from side
branch obstruction (Ormiston and Serruys, 2009). Realization
has been hampered by material performance inferiority in
comparison to permanent metallic counterparts. Two-year
follow–up on patients treated with the Abbott ABSORB BVS
stent showed an 11% rate of major adverse cardiac events (e.g.,
cardiac death, heart attack, additional procedures) in comparison
to a 7.9% rate for patients treated with the metallic XIENCE
drug eluting stent. Furthermore, an increased rate of thrombus
formation was observed with the BVS compared to the XIENCE
stent (1.9% in BVS versus 0.8% in XIENCE) (Maisel, 2017). The
current state of the art absorbable polymer stent technologies
(including ABSORB) rely on the polymer poly–L–lactide (PLLA)
(Gupta et al., 2007; Iqbal et al., 2013; Verheye et al., 2014), which
displays a relatively high elastic modulus with a low elongation at
break. PLLA’s high crystallinity and glass transition temperature
(Tg of 60
◦C) result in relatively brittle behavior in medical
application (Fernández et al., 2012). Furthermore, polymers
used in bioresorbable stent (BRS) technologies thus far have
presented considerably lower ultimate tensile strengths (UTS)
with respect to gold standard metals. Thus, the application is
hampered by fracture risks, strut thickness limitations, recoil,
deployment limitations and limited expansion among a host
of new challenges arising with degradable devices including
degradation profile, biocompatibility of by-products, shelf-life
concerns, and reduction in mechanical strength as degradation
proceeds (Khamis et al., 2014; Collet et al., 2016; Foin et al., 2016;
McMahon et al., 2018).
Copolymers offer a potential solution to address many
of the homo-polymer performance limitations in absorbable
stent devices without significantly compromising relevant
material properties that make PLLA such a useful candidate.
Copolymerizing of lactide with small amounts of ε-caprolactone
(Fernández et al., 2012) yielded a reduced Tg and crystallinity,
thus improving the elongation at break and presenting a valuable
performance tuning opportunity (Ugartemendia et al., 2015). In
addition, polyethylene glycol functionalization offers potential
to tailor the surface properties in terms of hydrophilicity and
therefore control cellular adhesion and responses. PEG grafting
techniques are typically multi-step approaches (Kingshott and
Griesser, 1999; Lieb et al., 2003; Shin et al., 2009; Vasilev
et al., 2010; Melchiorri et al., 2013) which are difficult to
translate to the complex architectural design of stents post
fabrication. Furthermore, there are significant challenges in
stabilizing PEG grafts through the processes of crimping,
sterilization, storage and expansion of a stent. With polymer-
based stents, there is a new opportunity to solve these issues via
incorporation of PEG in the raw materials chemical structure
adding significant application potential and by-passing complex
grafting procedures (Kim et al., 2011; McMahon et al., 2016).
Short PEG end chains (Mw 550 Daltons) were carefully selected
to ensure bioresorption of this PLCL solution is not compromised
since low molar mass PEG may be eliminated from the body
safely (Jeong et al., 2004; Webster et al., 2007).
Combining the two strategies (PEG copolymerization with
PLCL copolymers) we have systematically created polymer series
that allows refined control over a wider degree of material
performance which will become an important biomedical device
strategy in future. These polymers have been synthesized using
a proprietary approach yielding a cleaner polymer lacking
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solvent residues therefore inherently reducing the risk of
adverse inflammatory effects on the patient and removing the
risk of solvent residue interactions with active pharmaceutical
ingredients or therapy (Barnes and Harris, 2008).
Here, we present the results of in vitro biocompatibility
assessment of these new chemically defined
lactide/caprolactone/PEG copolymers using a panel of five
cell-based tests. While in vitro biocompatibility evaluation of
medical devices is described by a series of standards collectively
under the ISO 10993 set, it does not include available assays that
may be more relevant to a cardiovascular application. Therefore,
we selected a panel of five in vitro tests to easily screen and
thoroughly evaluate the cyto- and hemocompatibility of the new
materials. On the one hand, we performed the tests required
by ISO 10993-5 standard comprising material toxicity testing
according to the multiplex assay format and hemolysis testing
(ISO 10993-4) (Beuth Publishing, 2009, 2017). In addition,
we analyzed the materials’ thrombogenic and inflammation
inducing properties. Since ECs maintain a non-thrombogenic
blood-tissue interface, regulate thrombosis, thrombolysis,
vascular tone and blood flow in their basal state they are
considered the ideal non-thrombogenic and non-inflammatory
surface (Galley and Webster, 2004). We analyzed EC adhesion
to the materials to assess their usefulness in facilitating fast
and complete reendothelialization. Platelet adhesion and
morphology was used to analyze thrombus formation risk and
a leucocyte activation assay based on PMN elastase release was
used to test for inflammatory induction. Together, these tests
allowed a more in-depth view on all relevant properties of a
cardiovascular device material which ideally should be non-
toxic, non-hemolytic, non-thrombogenic, non-inflammatory
and facilitate EC adhesion.
RESULTS
Polymers
Synthesis
PEG-functionalized PLCL polymers of varying composition
(lactide to caprolactone of 90:10, 80:20, 70:30 and 55:45, see
Figure 1 for synthesis scheme and Supplementary Table S1
for a list of all polymers used in this study) were synthesized
using a proprietary polymerization approach. Molecular weight
analysis by gel permeation chromatography (GPC) showed
that all polymers presented medium to high relative molecular
weights and relatively low polydispersity (PDi range of 1.5–2.4,
see Table 1).
The molecular weights were large enough to exceed a critical
value for entanglement formation thus allowing comparison
across the series. Relative fractions of lactide to caprolactone were
confirmed by 1H-NMR to lie within an acceptable ± 2 molar
fraction of the target molar ratios while polymer purity with
respect to monomer residues was ≥98% for lactide monomer
conversion and ≥96% for caprolactone monomer conversion
(see Table 1). Furthermore, presence of PEG was confirmed by
the appearance of a peak at a chemical shift of 3.65 ppm in all
PEG-functionalized polymers.
Surface Properties of Polymer Films
For the analysis of in vitro biocompatibility films of PEG-
functionalized polymers and non-functionalized controls were
prepared and their surface properties examined via water contact
angle (WCA) measurement, FTIR-ATR and SEM (see Table 2 for
a summary on all film surface results).
Water contact angle analyses were conducted in order to
get a first impression on film surface characteristics, especially
hydrophilicity (see Supplementary Figure S2). Films of the
controls PLLA and PCL exhibited contact angles of 80 ± 3◦ and
76 ± 10◦, respectively while incorporation of PEG resulted in
a significant reduction of contact angles for the PLLA-PEG550
and PCL-PEG550 films to 70 ± 2◦ and 61 ± 8◦, respectively.
Contact angles of the PLCL-PEG series films were lower than
non-PEGylated controls while a slight but significant increase
was observed with increasing caprolactone content from PLCL-
PEG550 90:10 and 80:20 to 70:30 and 55:45.
Polymer film surfaces were analyzed by FTIR-ATR
measurement (Figure 2) which clearly proved the presence
of lactide and/or caprolactone in the films. The most prominent
indicator of PCL presence was the band at 2945 cm−1
(asymmetrical stretching of CH2, see details on PCL-specific
signals in Supplementary Table S3) while in case of PLLA a
distinctive signal pattern was observed in the range from 1250
to 1000 cm−1 (particularly the symmetrical stretching mode
C-CH3 at 1045 cm
−1, see details on PLA-specific signals in
Supplementary Table S4) (Schrader, 1995; Oliveira et al., 2013).
Using these signals presence of polylactide could be shown in
PLLA, PLLA-PEG550 and all candidates of the PLCL-PEG series
while caprolactone presence was observed in PCL, PCL-PEG and
the PLCL-PEG series. Here, the normalized signal intensities of
the caprolactone specific 2945 cm−1 signal actually increased
with increasing content of caprolactone in the polymer, while
the main PLLA signal decreased. The stretching vibration of the
carbonyl group was observed as a prominent peak at 1756 cm−1
for PLA containing polymers and at 1723 cm−1 for PCL. In
the mixed polymers, the band at 1723 cm−1 for PCL could
only be observed as a shoulder. A shift to lower wavelength
also is indicative of increased crystallinity which is the case in
PCL and PCL-PEG550. Also, in the two polymers with higher
caprolactone content (PLCL-PEG70:30 and 55:45) the shoulder
to lower wavelength indicates crystallinity which was more
pronounced in PLCL-PEG550 55:45. Presence of PEG could not
be shown using this method since PEG signals are overlapping
with PLA and PCL signals (see details on PEG-specific signals in
Supplementary Table S5).
SEM revealed a good surface quality for all polymer films as
shown in Figure 3. In all cases, the films were flat and well-
formed without presence of air bubbles or holes, whereas these
polymers presented differences in terms of surface morphology
and topography. Since all film casting was conducted using the
same approach, changes in surface morphology can be accredited
to the variance in polymer physical properties. In case of PLLA-
PEG550, we observed a very smooth surface with no irregularity
in terms of surface structuring. PLCL-PEG550 90:10, PLCL-
PEG550 80:20, and PLCL-PEG550 70:30 were similar in surface
quality showing mild deviation from the flat surface observed
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FIGURE 1 | Structural overview on each reaction for the synthesized PEG functionalized materials (A) PCL-PEG, (B) PLLA-PEG, and (C) PLCL-PEG.
TABLE 1 | Results summary of GPC and 1H-NMR analyses of synthetic polymers.
Material Mn /kDa Mw /kDa PDi
a) LA CL PLA PCL PEG
PLLA 374.2 584.6 1.52 0.99 – 1.0 – –
PLLA-PEG550 236.6 347.8 1.47 0.98 – 1.0 – +
PCL 61.6 115.0 1.87 – 0.99 – 1.0 –
PCL-PEG550 77.8 175.4 2.26 – 0.99 – 1.0 +
PLCL-PEG550 90:10 116.7 279.8 2.40 0.99 0.99 0.88 0.12 +
PLCL-PEG550 80:20 91.0 164.5 1.81 0.99 0.98 0.80 0.20 +
PLCL-PEG550 70:30 101.3 177.3 1.75 0.99 0.96 0.68 0.32 +
PLCL-PEG550 55:45 83.4 139.8 1.68 0.99 0.99 0.56 0.44 +
Polymer number average molecular weight (Mn) and weight average molecular weight (Mw) were determined by GPC while polymer monomer purity (lactide: LA
and caprolactone: CL), copolymer molar fractions (polylactide: PLA and polycaprolactone: PCL) and presence of PEG were confirmed by 1H-NMR. a)Polydispersity
index = Mw/Mn; The values for Mn and Mw resulted from individual determinations.
in PLLA-PEG550 although PLCL-PEG550 90:10 exhibited a
slightly roughened surface. All of these polymers had large lactide
fractions leading to relatively similar film formation and surface
behavior. Whereas the PLCL-PEG 55:45 material yielded films
that presented a more ordered surface morphology with slight
elevations created in the form of rising ridges of approximately
1 µm diameter. This can be accredited to the highly elastomeric
behavior of this polymer allowing it the flexibility to form these
ridges (Fernández et al., 2012). PCL showed a very ordered
surface morphology with obvious surface patterns of crystalline
areas. PCL-PEG550 was the most crystalline, where the film
surface presented spherulite structures.
In vitro Cell Compatibility
Films of PLCL-PEG copolymers were evaluated using a panel
of different in vitro methods – according to ISO 10993 and
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TABLE 2 | Summary of film surface properties.
Material Contact anglea) PLAb) PCLb) Crystallineb) SEMc)
PLLA 79.5◦ ± 3.2 + – No –
PLLA-PEG550 69.8◦ ± 2.3 + – No Flat and smooth
PCL 76.4◦ ± 10.2 – + Yes Spherulitic structure
PCL-PEG550 61.2◦ ± 7.5 – + Yes Spherulitic structure
PLCL-PEG550 90:10 65.5◦ ± 4.1 + + No Flat but roughened
PLCL-PEG550 80:20 67.2◦ ± 3.1 + + No Alternating smooth and roughened areas
PLCL-PEG550 70:30 75.5◦ ± 2.0 + + Yes Flat and smooth
PLCL-PEG550 55:45 72.3◦ ± 6.1 + + Yes Homogeneous ridged structure
Water contact angles, presence of polylactide(PLA) and polycaprolactone (PCL) as determined by FTIR, FTIR evidence of crystalline surface and SEM appearance
are presented. a)see Supplementary Figure S2; b)see Figure 2 for FTIR graphs and Supplementary Tables S3–S5 for FTIR peak summary; c)see Figure 3 for
SEM micrographs.
FIGURE 2 | FTIR-ATR spectra of PCL (PC12) and PCL-PEG550, PLLA (PL38) and PLLA-PEG550 and the PLCL-PEG550 series. The figures show overview spectra
(left side) and zoom-in spectra (right side) of the 650 – 1800 cm-1 wavenumber region.
beyond. Here, we were specifically interested in the effect the
new materials had on cells present at a stent implantation site
(especially different types of blood cells and endothelial cells).
Toxicity Testing With L929
First of all, we tested if the materials caused any adverse reactions
in a standard cell line as suggested in ISO 10993-5 (Beuth
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FIGURE 3 | Representative SEM pictures of material films in different
magnifications.
Publishing, 2009). Since finally, cardiovascular implants will be
in direct contact with the vessel wall we chose a direct contact
multiplex assay format which allowed parallel determination of
the amount of attached cells (“Viability”), the amount of dead
cells (“Toxicity”) and the amount of cells undergoing apoptosis
(“Apoptosis”). Cell attachment and proliferation on materials
(“Viability”) was the same or only slightly reduced on film
samples compared to the ideal surface of tissue culture-treated
polystyrene (TCPS) (Figure 4). Since in addition, no material
toxicity was observed all presented polymer films can be rated as
non-cytotoxic. Also, none of the lactide/caprolactone materials
led to significantly increased apoptosis induction compared
to TCPS control.
Hemolysis
Hemolysis testing is required for the evaluation of biomaterials
intended for stent devices according to ISO 10993-4 (Beuth
Publishing, 2017). It is a sensitive indicator of the destructive
degree of a material to erythrocytes. Among the tested
biomaterials only PLCL-PEG 55:45 showed an elevated hemolysis
rate of 2.5% ± 0.5 (Figure 5). All other materials showed rates
smaller than 2%. However, the increase in hemolysis on the
surface of the material PLCL-PEG550 55:45 compared to the
other materials and in relation to the threshold value of 2% was
significant after Bonferroni correction (for criteria see review by
Van Oeveren, 2013).
Platelet Adhesion and Morphology
Platelet adhesion together with morphology of adhered platelets
is a common indicator to evaluate hemocompatibility of
newly developed biomaterials more precisely their thrombus
formation potential. Based on their shape, adhered platelets
can be classified into five categories (Supplementary
Table S6), whereby only category V platelets might also
form aggregates and are indicative of material thrombogenicity
(Ko et al., 1993).
In our study clear differences in platelet adhesion onto
the various materials were observed as can be seen in the
representative micrographs in Figure 6. While most materials
showed low platelet adhesion and spreading, PCL control,
PCL-PEG550 and PLCL-PEG550 90:10 exhibited high platelet
adhesion rate accompanied by spreading to a fully spread
(category V) state and formation of aggregates which indicates
potential thrombogenicity of these materials. Among these, the
PCL control showed most adhesion with the formation of a
complete carpet of spread platelets and the presence of many
aggregate buds. Onto PCL-PEG550 and PLCL-PEG550 90:10
platelet adhesion occurred in a grouped order with free spaces
in between. PLLA exhibited slightly more adhered platelets
than PLLA-PEG550.
Leucocyte Activation
PMN elastase expression levels are an indicator for leucocyte
activation since inflammatory stimulation of neutrophils – the
most abundant leucocytes – results in the rapid release of high
amounts of this proteolytic enzyme (Alam et al., 2012). Here, we
analyzed PMN elastase release after 1 h of incubation between
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FIGURE 4 | Lactide/caprolactone film cytocompatibility was analyzed in
multiplex format using L929 cell line. L929 cells were seeded directly onto
material disks and grown for 24 h. Cell viability of attached cells was
measured using CellTiter-Blue assay and results are depicted in % compared
to TCPS. Cytotoxicity was analyzed using CytoTox-ONE assay, whereby lysed
cells were used as positive control (100% of cell lysis) and apoptosis induction
was determined using ApoONE assay, by using staurosporine induced cells
as positive control (100% of apoptosis). Measurements were carried out in
quadruplicate.
whole blood and material films (Figure 7). Most of the presented
materials showed no significant increase in leucocyte activity. The
PMN elastase value for PLCL-PEG550 90:10 was increased on
average, but did not turn out to be significant compared to the
control. In contrast, the value for material type PLCL-PEG550
55:45 showed a significant increase.
Endothelial Cell Adhesion
Since re-endothelialization is thought to greatly improve anti-
thrombotic and anti-restenotic properties of a surface we
FIGURE 5 | Hemolysis ratios of the tested biomaterials after 1 h of incubation
with diluted whole blood at 37◦C. Hemolysis of the empty well (PS) was set to
0 while lysis control equals 100%. PLCL-PEG550 55:45 exhibited significantly
increased hemolysis with ∗p < 0.006 after Bonferroni correction.
analyzed each material’s potential to facilitate endothelial
cell adhesion using primary human cardiac microvascular
endothelial cells (HCMECs). Representative micrographs of
attached HCMECs 24 h after seeding onto the different
materials and stained using live/dead staining are depicted in
Figure 8 and average cell numbers are given in Figure 9.
Although cells on PEGylated lactide/caprolactone films were
viable indicating again that the materials are non-toxic, big
differences in number of attached cells and cell morphology
were observed. From the described materials PCL-PEG550 and
PLCL-PEG550 90:10 showed highest cell adhesion accompanied
by a high grade of spreading. While on PCL-PEG550 ECs
appeared in ordered groups cell adhesion in case of PLCL-
PEG550 90:10 the ECs seemedmore evenly distributed. Although
even more endothelial cells were able to attach onto PLCL-
PEG550 70:30, cells had a rounder shape and cluster formation
was observed. Among the tested samples PLLA-PEG550 and
PLCL-PEG550 55:45 exhibited lowest cell numbers and nearly no
spreading was seen.
DISCUSSION
PLCL-PEG Copolymerization Strategy
Resulted in Highly Accurate Composition
Copolymerizing lactide with caprolactone and incorporating a
polyethylene glycol end chain has been successfully achieved. The
intended molar ratios of lactide to caprolactone (100:0, 90:10,
80:20, 70:30, 55:45, 0:100) were achieved with high accuracy
to an industrial standard and within ±2 moles of the target
molar fractions (Table 1). The presence of PEG (Mn = 550
Da) was confirmed using 1H-NMR while all synthesized
polymers presented low polydispersity indexes and outstanding
control. Furthermore, copolymers were synthesized with high
molecular weights (Mw = 128 – 348 kDa) which remains
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FIGURE 6 | Continued
FIGURE 6 | Representative micrographs of platelet adhesion onto the
lactide/caprolactone polymer films. Platelet-rich plasma was incubated for 1 h
on film samples and adherent platelets were visualized using F-actin staining.
Micrographs of 500x magnification give an overview (scale bar corresponds to
50 µm) while micrographs of 2500x magnification show platelet morphology
in more detail (scale bar corresponds to 10 µm).
FIGURE 7 | Leucocyte activation during a 1 h blood/biomaterial interaction
was analyzed using PMN elastase ELISA assay. The baseline PMN elastase
expression in non-activated blood in an empty PS well was set to 100%. An
exemplary induction of leucocyte activation was achieved by the addition of
bacterial lipopolysaccharides (LPS). Measurements were carried out in
quadruplicate, ∗p ≤ 0.05; ∗∗p ≤ 0.01.
challenging with conventional polymerization procedures
(Auras et al., 2004; Lasprilla et al., 2012). Polymerization
reported herein is even more impressive considering that
these polymers were produced entirely in the absence of toxic
organic solvents yielding cleaner biomaterials that elicit lowered
inflammatory response.
Film Surface Characteristics
Using WCA measurements, FTIR-ATR and SEM imaging
we confirmed the high quality of our film preparation
and analyzed the surface characteristics in more detail (see
Table 2 for summary). While all films were flat without
the presence of air bubbles and holes, differences in their
surface morphologies and topographies were observed. Surface
texturing was observed in PCL and PCL-PEG550 in form of
spherulite crystallization as seen in SEM images (Figure 3)
which was also confirmed by the presence of a typical band
shift of the carbonyl peak in FTIR (Figure 2). This surface
inhomogeneity also explains the higher variance in contact
angle measurements. PLCL-PEG550 55:45 was shown to exhibit
high grade of crystallinity which was represented in SEM
in the formation of ridged structures and in FTIR by the
existence of a lower wavelength shoulder of the carbonyl
peak. These changing surface properties relate to the solvent
casting process and material behavior. Since all films were
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FIGURE 8 | Representative micrographs of adherent endothelial cells on the different lactide/caprolactone materials stained with Live/Dead staining. The cells were
seeded directly onto material films, incubated for 24 h and stained (green: cytoplasm of viable cells, red: nuclei of cells with damaged cell membrane). Bar
corresponds to 100 µm.
cast using the same method, we believe that material behavior
leads to the formation of a slightly varied surface quality. No
clear trend was observed in the other PEG-modified films:
While PLLA-PEG550 and PLCL-PEG550 70:30 exhibited smooth
surfaces PLCL-PEG550 90:10 showed slight surface roughness
and PLCL-PEG550 80:20 consisted of smooth areas and more
roughened areas.
All PEG-containing materials showed lower water contact
angles than the controls – although to different degrees –
indicating that PEG addition increased hydrophilicity. This also
proves that PEG groups were present at the surfaces of all sample
films whereby hydrophilicity was highest in PCL-PEG550, PLCL-
PEG550 90:10 and 80:20. The values for PEG functionalized
PLCL films were significantly lower than values reported in
the literature for non-PEGylated lactide-caprolactone polymers
owing to the incorporation of PEG in the polymer structure (Lim
et al., 2008; Inthanon et al., 2016).
In vitro Biocompatibility
Copolymerization Method Has No Negative Effect on
Cells
General cytocompatibility testing as required by ISO 10993-
5 (Beuth Publishing, 2009) was conducted in direct contact
format – seeding the L929 cells directly onto film samples –
because the materials are intended as cardiovascular materials
that will directly be colonized in vivo. With L929 cell line
no significant differences in number of viable adherent cells
were observed among all tested materials. Thus, together with
the results of absolutely no toxicity, we concluded that the
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FIGURE 9 | Number of viable endothelial cells attached to material disks. The
cells were seeded directly onto material films, incubated for 24 h and counted
after Live/Dead staining. At least 10 microscopic images were counted per
material. Bar shade indicates cell morphology (from dark gray = good
spreading, normal morphology to light gray = mostly non-spread); ∗p ≤ 0.01.
presented copolymerization strategy generated completely non-
toxic materials. In addition, no other adverse effects as measured
by apoptotic induction were observed.
Hemolysis on the one hand is a measure of blood toxicity
(Beuth Publishing, 2017) for example originating from residual
solvent in the polymer. On the other hand, specific material
surface structures might cause blood cell rupture. Here, we found
that PLCL-PEG copolymers were non-toxic to blood erythrocytes
although possibly topography related slightly elevated hemolysis
was observed in case of PLCL-PEG550 55:45. As seen in SEM,
this material exhibited a high degree of surface irregularity in the
form of ridges of approximately 1 µm diameter that seem to be
able to lacerate red blood cells. PEG incorporation was shown
to prevent hemolysis in a hemolytic material (Wang et al., 2010)
but the ridges presented by PLCL-PEG550 55:45 seem to be too
sharp so that the presence of PEG was partially overcompensated
by the topographic effect. Surface patterning is a well-known and
important tool that can be used to enhance biocompatibility of
these materials for medical applications while here we can also
see the potential for adverse impact that an uncontrolled surface
may have (Pacharra et al., 2019).
Cell Adhesion and Activation Can Be Fine-Tuned by
Polymer Composition
In addition to mandatory testing required for every material
intended for implant use, we wanted to obtain more information
regarding a possible use of these materials as cardiovascular
implants. Since stents and vascular grafts will be in contact to the
vessel wall and the blood, we chose three additional direct contact
assays to analyze thrombogenic and inflammatory properties,
and endothelialization.
Platelet adhesion, as an indicator of possible material
thrombogenicity, in general could be reduced by the presence of
PEG chains on the films compared to controls without PEG –
although the extent depended on the polymer type. It has already
been shown that the presence of PEG on the surface of a material
leads to the formation of more inert surfaces with reduced cell
adhesion capabilities for various materials (Chuang and Masters,
2009; Noel et al., 2015) while Chen et al. (2011) found that
the degree of adhesion reduction might vary depending on
the type of PEG. In case of PCL-PEG550 substantial platelet
adhesion and spreading but less aggregation was observed than
on un-PEGylated PCL. From film characterization via SEM, we
know that these polymer surfaces presented ordered spherulitic
structures which may have caused an enhanced affinity for
platelet adhesion. In addition, the high platelet adhesion on both
PCL and PCL-PEG550 might be due to the partial presence of
negatively charged carboxyl groups at the film surface as was
already described for carboxyl presenting surfaces (Sperling et al.,
2009). In contrast, the very smooth and uncharged surface of
PLLA and PLLA-PEG550 offered little attachment points for
platelets while the presence of PEG further reduced platelet
adhesion and spreading. This indicates that PEG chains were
presented to the solid/liquid interface of this material. In case
of the PLCL-PEG550 series the observed differences in platelet
adhesion and spreading originated in the different morphologies.
As the caprolactone content increased in the copolymer samples
PLCL-PEG550 90:10 to 55:45, we observed that the platelet
adhesion and spreading decreased. In all samples the content of
caprolactone was low, not enough to create a negatively charged
surface similar to that of the pure PCL-PEG550 which furthered
platelet adhesion.
Overall, the lactide/caprolactone materials did not lead to
substantial leucocyte activation as tested on the basis of PMN
elastase release from neutrophils in human whole blood. In
contrast, PLCL-PEG550 55:45 showed a significant increase in
PMN elastase levels. In the case of PLCL-PEG550 55:45, the
effect of surface irregularities, which has already been described
in hemolysis, may come into play again and seems to be
responsible for the slightly increased hemolysis activity. So far,
the mechanism of neutrophil activation by a material surface
is not clearly understood but surface chemistry and topography
have been shown to influence neutrophil behavior (Tan et al.,
2000; Patel et al., 2006). Thus, PLCL-PEG550 55:45 might lead
to partial activation of neutrophils because of its roughened or
ridged surface structures, respectively.
Since rapid and complete endothelialization is thought to
greatly improve cardiovascular implant biocompatibility we
also tested endothelial cell adhesion using primary human
cardiac microvascular endothelial cells (HCMECs) – a cell type
actually present in the coronary vasculature. We found that
EC adhesion and spreading gradually increased with increasing
lactide content and decreasing crystallinity as did platelet
adhesion and spreading. This suggests that PEG presentation is
strongly affected by polymer chain orientation and alignment. In
PLCL-PEG550 90:10 it seemed that PEG was not accumulated
at the film surface possibly due to the random polymer
orientation of this amorphous material allowing cell adhesion.
In contrast, PEG chains seemed to be evenly enriched at the
surface of the highly crystalline PLCL-PEG550 55:45 resulting
in a cell-repellent more inert surface. Thus, the presented
copolymerization of lactide/caprolactone/PEG allows gradual
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tuning of cell adhesion properties. On the smoother materials
with a better presentation of PEG chains to the interface (e.g.,
PLLA-PEG550) cell adhesion of endothelial cells and platelets
was much lower.
In vivo, a fast and complete endothelialization might greatly
influence the hemocompatibility of materials. On the one hand,
the presence of an endothelial cell layer can cover the foreign
surface from direct contact with blood cells and thereby hinder
blood cell activation. In addition, healthy endothelial cells
can actively prevent thrombus formation and inflammatory
responses (de Mel et al., 2008; Ren et al., 2015). Therefore,
PCL-PEG550, PLCL-PEG550 90:10, and PLCL-PEG550 70:30,
which showed good endothelial cell coverage, might be promising
candidates for cardiovascular implant production. This will be
studied in more detail in the future by more advanced in vitro
testing (for example in a bioreactor under flow conditions) or in
animal experiments.
EXPERIMENTAL SECTION
Materials
All customized polymer formulations (PLLA-PEG550,
PLCL9010-PEG550, PLCL8020-PEG550, PLCL7030-PEG550,
PLCL5545-PEG550, PCL-PEG550) were supplied by Ashland
Specialties Ireland Ltd. (Dublin, Ireland). PL38 and PC12 with
inherent viscosity of 3.8 and 1.2 dl/g respectively were used as
controls and supplied from Purac (Gorinchem, Netherlands).
Chloroform (CHCL3 and CDCL3) were supplied from Sigma
Aldrich and used for all film casting, GPC and NMR testing.
Polymer Synthesis
PEG-functionalized PCL, PLLA and PLCL of varied composition
were synthesized by Ashland Specialties Ireland Ltd. Briefly,
these polymers were achieved through the Ring-Opening
Polymerization (ROP) of the monomers L-lactide and ε-
caprolactone using the catalyst stannous octoate initiated by
the hydroxyl terminal group of the relevant initiation molecule
(polyethylene glycol methyl ether). This resulted in polymers
consisting of long chains of PLLA, PCL or PLCL connected to a
singular PEG end group. In each polymerization reaction, pre-
determined amounts of monomer, initiator and catalyst were
added to the autoclave and were then heated to the reaction
conditions. This reaction achieved good reaction control in terms
of target molar mass, monomer conversion and a relatively low
polydispersity polymer. A structural overview on each reaction is
presented in Figure 1 and a summary of all materials used in this
study is given in Supplementary Table S1.
Characterization of Polymer
Composition
Gel permeation chromatography (GPC) measurements were
performed using an Agilent triple detector system which was
calibrated with polystyrene standards at a concentration of
10 mg/ml. Chloroform (CHCL3) was used as mobile phase with
a flow rate of 1.0 ml/min. Weight average molecular weight
(Mw), number average molecular weight (Mn) and polydispersity
(PDi) data were collected using refractive index peak height
in the range of <10 mV. For each polymer 3–7 mg powder
was dissolved in 2 ml chloroform and filtered [0.2 µm pore
size, 13 mm diameter, Millipore SLFG013NL, Fluropore PTFE
(F) membrane]. An Agilent Technologies column (PLgel, 5 µm
MIXED-C, 300× 7.5 mm) was used for GPC analysis.
Proton nuclear magnetic resonance spectroscopy (1H-NMR)
was utilized for identification of the polymer, confirmation of
the polymer purity in terms of monomer conversion, molar
ratio of relevant copolymer units and to confirm the presence
of PEG in the chemical structure. A 300 MHz Bruker NMR
machine was used to obtain the spectra which were analyzed
and processed using MestReC software package. Deuterated
chloroform (CDCl3) was used to dissolve the polymer which was
then filtered using a Milnex (0.2 µm) into NMR sample tubes.
Lactide methyl presented a signal centered around 5.16 ppm and
caprolactone on 4.02 ppm while PEG presence was identified at a
chemical shift of 3.65 ppm (Wu et al., 2010). These signals were
taken as reference points for the determination of the polymer
composition given in Table 2. From the 1H-NMR we observed
the polymer conversion based on the CH3 and CH peaks for
respective polymers and monomers introduced.
Polymer Film Preparation
Film casting was achieved by dissolving 0.5 g of polymer in 15 ml
of chloroform. Each solution was dissolved until transparency
and poured into a glass petri dish of dimensions 60mm× 15mm.
Chloroform was evaporated overnight resulting in thin uniform
films which were peeled from the glass surface once solvents had
evaporated entirely.
Analysis of Film Surface Properties
Water contact angle was measured to analyze the wettability
of the film samples. This study was carried out using KSV
Cam 200 optical goniometer (Helsinki, Finland). Hundred µl of
deionized water was dropped on the surface of the films using
a micro-syringe. Images were captured with a frame interval
of 1 s. KSV Cam software was used to analyze the images.
This was done at Eastman Dental Institute, University College
London, United Kingdom. For each material, the contact angles
of three independent samples were measured with at least 10
measurements per sample.
Fourier transform infrared (FTIR) spectroscopy was
performed as attenuated total reflectance (ATR) measurement.
Spectral manipulations were performed by spectroscopy software
OPUS provided by Bruker.
The ATR measurements were performed by a Tensor 27
FTIR spectrometer from Bruker, equipped with a VariGATRTM
ATR accessory, with a resolution of 4 cm−1, for each sample
using 50 scans. The spectra were acquired by a liquid N2 cooled
mercury cadmium telluride (MCT) detector, in the range of
4000–600 cm−1.
Scanning electron microscopy (SEM) images were obtained
using a Quanta 3D FEG scanning electron microscope (FEI).
Samples were cut from the central part of the produced films
and were fixed on a commercial aluminum stub with conductive
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carbon tape (Plano), in a way that a part of the film sample was
overlapping and no contact to the stub or carbon tape occurred.
This part of the sample has always been analyzed. The optimum
in image quality was obtainedwith an acceleration voltage of 2 kV,
a spot size of 4.5 and a working distance of around 10 mm. Under
these conditions no or a minimum of degradation of the sample
during imaging was observed.
Toxicity Testing With L929 (Multiplex
Assay)
The mouse fibroblast cell line L929 was obtained from
DSMZ (Leibniz-Institut DSMZ - Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH) and
handled according to their manual. Briefly, L929 cells were
grown in RPMI 1640 medium (PAN Biotech, Aidenbach,
Germany) supplemented with 10% FBS (PAN Biotech) and
a penicillin/streptomycin mixture (Thermo Fisher Scientific,
Dreieich, Germany) in an incubator (37◦C, 5% CO2). For
subculturing cells were detached using 0.25% Trypsin solution
(Thermo Fisher Scientific).
This multiplexed assay was adapted from Neuss et al.
(2008). From each polymer film disks of 6 mm diameter were
generated by punching. Disinfection was achieved by incubation
in 70% ethanol followed by washing with sterile water and
equilibration in medium. Material disks of 6 mm in diameter
were placed into the wells of a 96 well polystyrene(PS) plate
and fixed with Teflon rings. Tissue culture-treated polystyrene
(TCPS, Nunc) plates were used as controls for ideal cell
growth. L929 cells (2·104 cells per well) were seeded on top
of the disks and grown for 24 h under standard cell culture
conditions. Blank values were obtained from wells without
material disks and cells. As a positive control for cytotoxicity
cells grown on TCPS were lysed prior to assaying. As a
positive control for apoptosis 100 nM staurosporine (Santa
Cruz Biotechnology, Heidelberg, Germany) was added to cells
grown on TCPS 6 h after seeding. Each sample was analyzed
in quadruplicate.
After 24 h of incubation the cell culture supernatants
were transferred into black 96 well plates and subjected to
cytotoxicity analysis using the CytoTox-ONETM Homogeneous
Membrane Integrity Assay (Promega, Mannheim, Germany)
following the manufacturer’s protocol. After equilibration to
ambient temperature assay reagent was added to each well in a
1:1 ratio and incubated for 10 min. The reaction was stopped
by addition of Stop Solution and the fluorescence monitored
(excitation: 560 nm, emission: 590 nm).
Directly after supernatant removal for cytotoxicity analysis
cell viability was analyzed using the CellTiter-Blue R© Cell Viability
Assay (Promega) following the manufacturer’s protocol. After
addition of the reagent/medium mixture plates were incubated
for 2 h at 37◦C, 5% CO2. Cell culture supernatant was transferred
to black 96 well plates and fluorescence monitored (excitation:
560 nm, emission: 590 nm).
Directly after supernatant removal for viability measurement
cells were subjected to apoptosis analysis using the Apo-ONE R©
Homogeneous Caspase-3/7 Assay (Promega) following the
manufacturer’s protocol. After addition of the reagent/medium
mixture plates were incubated for 2 h at ambient temperature.
The supernatant was transferred to black 96 well plates, incubated
for further 18 h and the fluorescence monitored (excitation:
485 nm, emission: 527 nm).
Blood Collection
Fresh human whole blood was obtained from healthy adult
volunteers (no medication (e.g., aspirin) in the previous 2 weeks)
by venipuncture into either S-Monovette 9 ml LH (Sarstedt,
Nümbrecht, Germany). Blood was collected at the Centre
for Translational Medicine, Medical Department I, University
Hospital of the Ruhr-University Bochum, Herne, Germany
according to appropriate legal and ethical guidelines. The
participants provided written informed consent to participate
in this study. The study was reviewed and approved by
the Ethics Committee of the Medical Faculty of the Ruhr-
University Bochum, Gesundheitscampus 33, D-44801 Bochum.
The registration number of the study is 16-5649.
Hemolysis
Hemolysis testing was done based on the protocol by Wang
et al. (2013) with slight modifications. Lithium heparin (LH)
blood was diluted 4:5 in 0.9% (w/v) sodium chloride (NaCl)
solution. Material disks of 14 mm diameter were placed into the
wells of a PS 24 well plate (Nunc, Fisher Scientific, Schwerte,
Germany) and fixed using silicone rings. After washing with
0.9% NaCl solution the disks were incubated for 30 min at
37◦C with 980 µl NaCl solution. As negative control the bare
PS was used and as positive control of complete red blood
cell lysis 980 µl of distilled water was added instead of 0.9%
NaCl. To each well 20 µl of pre-diluted blood was added, mixed
and incubated for 60 min at 37◦C with slow shaking. After
centrifugation at 700 × g for 10 min 200 µl of supernatant were
transferred to a 96 well plate and the absorbance was measured
at 542 nm using 691 nm as reference wavelength. Measurements
were done in quadruplicate. The hemolysis ratio (HR, in %)
was calculated as follows HR = (A – Cneg) / (Cpos – Cneg) x
100%, where A is the absorbance of the sample, Cneg is the
absorbance of the negative control and Cpos is the absorbance of
the positive control.
Platelet Adhesion and Morphology
Platelet-rich plasma (PRP) was isolated from LH blood according
to the description from Parnham and Wetzig (Parnham and
Wetzig, 1993). Briefly, whole blood was centrifuged at 250 × g
for 10 min and the supernatant (=PRP) was recovered.
Material disks of 14 mm diameter were placed into the wells
of a 24 PS well plate and fixed using silicone rings. After washing
with 0.9% NaCl solution three times the disks were incubated
at 37◦C for 1 h with 500 µl of PRP. Adhered platelets were
visualized using F-actin staining. Briefly, disks were washed three
times with PBS (PAN-Biotech), fixed with 4% formaldehyde (Life
Technologies, Darmstadt, Germany) in PBS, permeabilized with
0.4% Triton X-100 in PBS and blocked using 2% BSA in PBS.
After staining with PromoFluor 546 phalloidin (PromoKine) the
disks were mounted using Fluoroshield with PPD. Fluorescence
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microscopy was done with the IX 51 microscope (Olympus,
Hamburg, Germany). At least 2 independent samples were
visualized per material and at least 5 images of different areas per
sample were recorded.
Leucocyte Activation
Material disks of 14 mm diameter were placed into the wells
of a PS 24 well plate, fixed using silicone rings and disinfected
in 70% ethanol. After washing with 0.9% NaCl solution the
disks were incubated at 37◦C for 1 h with 500 µl of LH
blood. 100 ng/ml lipopolysaccharides (LPS) from E. coli (Sigma-
Aldrich, Schnelldorf, Germany) were used as positive control.
From each sample, the plasma was isolated by centrifugation at
1400× g for 15 min.
Leucocyte activation of these plasma samples was then
assessed based on expression analysis of polymorphonuclear
neutrophil (PMN) elastase using the PMN elastase ELISA
(Demeditec, Kiel, Germany) according to the manufacturer’s
protocol. Measurements were carried out in quadruplicate. The
concentration of PMN elastase was determined from absorbance
measurements by using the 4-parameter algorithm.
Endothelial Cell Adhesion
The primary human cardiac microvascular endothelial cells
(HCMEC) were obtained from PromoCell (Heidelberg,
Germany) and cultured according to the manufacturer’s protocol
in endothelial cell growth medium MV. Medium was changed
every 2–3 days while subculturing was performed at 70–90%
confluence using the detach kit from PromoCell.
The polymer films disks of 14 mm diameter were generated
by punching. Disinfection was achieved by incubation in 70%
ethanol followed by washing with sterile water and equilibration
in medium. Material disks were placed into the wells of a
24 well PS plate and fixed with Teflon rings. Cell-culture
treated polystyrene (TCPS) plates were used as controls for
ideal cell growth. Cells were seeded on top of the disks
(5·104 cells per disk) and grown for 24 h under standard cell
culture conditions. Staining was done using the Live/Dead Cell
Staining Kit II (PromoKine, Heidelberg, Germany) followed
by fluorescence microscopy using the IX 51 microscope. At
least 2 independent samples were visualized per material
and at least 5 images of different areas per sample were
recorded and counted.
Statistical Analysis
Values are given as mean together with the standard deviation
(number of replicates is given in each experimental section).
Statistical significance was determined using independent sample
t-tests. The Bonferroni method was used to adjust for multiple
comparisons (Noble, 2009).
CONCLUSION
A logical series of new copolymers have been synthesized for
application in a fully resorbable cardiovascular medical device
consisting of a bulk polymer of lactide and caprolactone
in systematic fractions and a polyethylene glycol end
functional group. Poly-(L-lactide-co-ε-caprolactone) with
lactide: caprolactone contents of 100:0, 90:10, 80:20, 70:30,
55:45, 0:100 have been successfully synthesized and evaluated.
Polymer chemical properties were well controlled with respect
to molar fractions, polymer purity, molar mass, PEG presence
and polydispersity. Excellent control over material chemistry
yielded a systematic spectrum of materials with tailored
copolymer fractions and thereby allowed us tomake comparisons
between subsets of chemical compositions and to draw relevant
conclusions.
Biological evaluation of material films revealed that all
polymers were non-toxic, non-apoptotic and did not induce
significant hemolysis while only the polymer PLCL 55:45-
PEG550 induced a mild hemolytic and leucocyte (PMN elastase)
response. This work indicated again that polymer chemistry
is only one angle while surface morphology had a significant
role to plan. From a hemocompatibility perspective, PLLA-
PEG550 and PLCL-PEG550 70:30 (non-toxic, non-hemolytic,
non-inflammatory and non-thrombogenic) presented the best
candidates for use in cardiovascular implants while from
a endothelialization perspective, PCL-PEG550, PLCL-PEG550
90:10, and PLCL-PEG550 70:30 showed best endothelial cell
adhesion. In light of the overall application target, it might
actually be more important in the in vivo situation to execute
this improved endothelial cell adhesion over platelet repelling
properties since a fully endothelialised surface is considered to
offer ideal hemocompatibility.
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